Project Summary
Severe pain caused by osteoarthritis (OA) affects over 15 million individuals in the United States alone. This
degenerative joint disorder not only poses a significant healthcare burden for the country’s aging society, but
also fuels the national opioid crisis, as no effective treatments exist to treat OA-induced joint pain. Disease-
modifying therapeutic development for OA typically involves mechanistic and preclinical studies in small animal
models (mouse, rat), followed by studies in large animal models (horse, pig) to confirm effectivity and safety.
Unfortunately, pain-modifying therapeutic development for OA has thus far been hampered by a limited
knowledge of the types of neurons that innervate the joint, the connections they form, and their functional or
circuit dynamics in the presence of joint disease. The RE-JOIN consortium strives to fill these knowledge gaps
by adapting and optimizing cutting-edge, multidisciplinary technologies to label, image, and profile joint-
innervating neurons and by applying them in small animal models and patients with OA. Here, we propose a
set of experiments that will be complimentary to RE-JOIN’s ongoing efforts. In this proposal, we aim to
leverage neuronal tracing and profiling technologies developed under parent grant (UC2-AR082200), applying
them to the equine carpal joint to identify and characterize joint-innervating neurons. We aim to identify the
dorsal root ganglia (DRG) that harbor carpal joint-innervating neurons (Viral neural tracing; Aim 1), develop
high-quality, complete transcriptomes of these DRGs that identify all tissue-specific isoforms (long-read RNA
sequencing; Aim 2), and perform multi-omic analysis of these DRGs to develop a spatial single cell reference
map that identifies the tissue’s individual cell types and their molecular fingerprints (spatial transcriptomics and
single nucleus RNA sequencing; Aim 3). The equine osteochondral chip model of post-traumatic OA has been
an excellent bridging translational model from small rodent to humans. The successful completion of research
proposed here will yield high-quality resources that will be shared with the scientific community, enabling future
studies to identify pain-mediating molecular and cellular changes that occur in the equine carpal joint
innervation during the development of joint disease. These resources will also enable translational researchers
to expand preclinical studies in equine models of OA to also include studies with chronic joint pain-modifying
therapeutic candidates, thereby increasing the likelihood of finding relevant new therapeutic targets to
effectively treat joint pain and/or solve the national opioid public health crisis.
Public Health Relevance Statement
Project Narrative
Post traumatic osteoarthritis (OA) can cause severe nociceptive and neuropathic pain that can negatively
impact the quality of life. Targeted development of joint-pain–modifying therapeutics has been hampered by
limited knowledge of the cellular and molecular pathways that mediate pain sensation in the joint, a knowledge
gap the RE-JOIN consortium is working to fill in small animal models and patients with OA. Here, we propose
to develop novel resources to enable preclinical and mechanistic studies related to joint pain in the horse, a
reliable large animal model of OA.
NIH Spending Category
No NIH Spending Category available.
Project Terms
3-DimensionalAccelerationAffectAfferent NeuronsAgeAgingAmericanAnatomyAnimal ModelArthralgiaCell NucleusCellsCervical spineChronicClinicCommunitiesComparative StudyCountryDataDegenerative polyarthritisDevelopmentDiseaseDisease ProgressionEquus caballusExerciseFamily suidaeFemaleFutureGenderGeneticGoalsHealth systemHelping to End Addiction Long-termHistologicHumanImageIndividualInterleukin-1JointsKnee jointKnowledgeLabelMapsMediatingMethodsModelingMolecularMolecular ProfilingMusNeuronsNociceptionOpioidOutcomePainPathologyPathway interactionsPatientsPhenotypeProtein IsoformsPublic HealthQuality of lifeRattusRegenerative MedicineResearchResourcesReview LiteratureRodentSafetySensorySignal TransductionSocietiesSpeedSpinal GangliaStructure of intercarpal jointTechnologyTherapeuticTissuesTracerTraumatic ArthropathyUnited StatesViralarthropathiescell typechronic pain patientclinical careeffective therapyexperienceexperimental studyfitnessgene therapyhealthcare burdenmalemouse modelmultidisciplinarymultiple omicsnerve supplyneuralnew growthnew therapeutic targetnovelopioid epidemicosteochondral tissuepain behaviorpain reductionpain sensationpainful neuropathyparent grantphase I trialpre-clinicalpreclinical studyscreeningsingle nucleus RNA-sequencingsocioeconomicstherapeutic candidatetherapeutic developmenttherapy developmentthoracic vertebra bone structuretooltranscriptometranscriptome sequencingtranscriptomicstranslational modeltranslational scientisttranslational study
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
846
DUNS Number
051113330
UEI
FXKMA43NTV21
Project Start Date
01-September-2024
Project End Date
31-August-2025
Budget Start Date
01-September-2024
Budget End Date
31-August-2025
Project Funding Information for 2024
Total Funding
$96,000
Direct Costs
$60,000
Indirect Costs
$36,000
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Neurological Disorders and Stroke
$96,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3UC2AR082200-01S1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3UC2AR082200-01S1
Patents
No Patents information available for 3UC2AR082200-01S1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3UC2AR082200-01S1
Clinical Studies
No Clinical Studies information available for 3UC2AR082200-01S1
News and More
Related News Releases
No news release information available for 3UC2AR082200-01S1
History
No Historical information available for 3UC2AR082200-01S1
Similar Projects
No Similar Projects information available for 3UC2AR082200-01S1